Boomi™, the leader in AI-driven automation, today announced a definitive agreement to acquire Thru, Inc., a provider of enterprise-grade Managed File Transfer solutions and trusted Boomi partner. The acquisition marks a strategic expansion of Boomi’s file-based integration capabilities, all within a single, cloud-native platform that seamlessly manages data movement across APIs, applications, and files. This press release features multimedia. View the full release here: https://www.businesswire...
New York Mobile is the first U.S. mobile virtual network operator (MVNO) to launch using Telness Tech’s newly launched Seamless OS platform. This deployment enables NY Mobile to deliver a next-generation wireless service, on T-Mobile’s largest and fastest 5G network. NY Mobile will be able to offer unprecedented features and flexibility for its customers including a vanity phone number marketplace and create-your-own-plan options. This press release features multimedia. View the full release he...
As part of the implementation of the commitments made in the joint declaration between His Majesty King Mohammed VI, may God Assist Him, and His Highness Sheikh Mohamed bin Zayed Al Nahyan, TAQA Morocco, in partnership with Nareva and the Mohammed VI Fund for Investment, has signed three memorandums of understanding and related development agreements with the Government of Morocco and ONEE. These agreements cover the development of structuring projects in the power, water and renewable energy s...
Dubai Electricity and Water Authority (DEWA) has started to receive applications for participation in the 27th edition of the Water, Energy, Technology, and Environment Exhibition (WETEX). Organised by DEWA in line with the directives of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and under the patronage of HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy, the exhibition will take place from 30 S...
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announced detailed results from the Phase 3, randomized, placebo-controlled VERIFY study evaluating rusfertide in patients with polycythemia vera (PV), which met the primary and all key secondary endpoints. The data will be presented as a late-breaking oral presentation at the 61st American Society of Clinical Oncology (ASCO) Annual Meeting Plenary Session (LBA3) at 2:09 pm CDT today. PV is characteriz...
Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for zoliflodacin, the investigational first-in-class, single dose, spiropyrimidinetrione oral antibiotic for the treatment of uncomplicated gonorrhea in adults and pediatric patients 12 years and older. If approv...